Comparative Pharmacology
Head-to-head clinical analysis: BAYCOL versus CRESTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAYCOL versus CRESTOR.
BAYCOL vs CRESTOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cerivastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing hepatic cholesterol production and increasing LDL receptor expression.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
Cervastatin 0.4 mg orally once daily in the evening, with or without food.
Oral, 5-40 mg once daily. Initial dose typically 10-20 mg; max 40 mg.
None Documented
None Documented
2-4 hours (terminal elimination half-life); clinical context: supports twice-daily dosing
The terminal elimination half-life is approximately 19 hours (range 13–20 hours). This long half-life allows once-daily dosing and provides sustained HMG-CoA reductase inhibition.
Renal: ~70% (mostly as unchanged drug); fecal: ~15%
Approximately 90% of rosuvastatin is eliminated in feces (as unchanged drug and metabolites), and about 10% is excreted in urine (mainly as unchanged drug). Biliary excretion is the primary route for elimination of metabolites.
Category C
Category C
Statin
Statin